Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Xiaobo Yang, MD
- Target Recruit Count
- 40
- Registration Number
- NCT05555641
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 1500
- Registration Number
- NCT05509647
- Locations
- 🇳🇱
Leiden University Medical Centre, Leiden, Zuid-holland, Netherlands
Nebulised Heparin in Patients With COVID-19 Pneumonia
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Lady Reading Hospital, Pakistan
- Target Recruit Count
- 180
- Registration Number
- NCT05255848
- Locations
- 🇵🇰
Pulmonology Department, Lady Reading Hospital, Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
Pretreatment with Unfractionated Heparin for ST Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 600
- Registration Number
- NCT05247424
- Locations
- 🇸🇮
UMC Ljubljana, Ljubljana, Slovenia
Safety and Feasibility of Argatroban as Anticoagulant in Adults With ECMO
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 40
- Registration Number
- NCT05226442
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 813
- Registration Number
- NCT05224388
- Locations
- 🇧🇪
Ghent University Hospital, Gent, Belgium
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 1100
- Registration Number
- NCT05204550
- Locations
- 🇦🇺
The Northern Hospital, Epping, Victoria, Australia
Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation
- Conditions
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 15
- Registration Number
- NCT05191290
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Australian National University
- Registration Number
- NCT05184101
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT05178550
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.